Repligen Corporation (NASDAQ: RGEN) has reported its first-quarter 2026 financial results, delivering a strong 15% increase in reported revenue to $194 million. The company's performance was bolstered by a surge in demand for Process Analytics and Chromatography, as well as a significant rebound in the Asia-Pacific (APAC) market.

For lab managers and bioprocessing professionals, Repligen’s results reflect a broader industry push toward real-time monitoring and highly efficient, scalable manufacturing workflows.

Process analytics and chromatography lead the way

The most striking figure in the Q1 report was the 50% growth in Process Analytics. This segment’s performance underscores a critical shift in modern laboratories toward automated, real-time data collection during bioprocessing.

"Q1-26 revenue growth was led by strength in Analytics and Chromatography," noted management in their supplemental presentation.

Key takeaways for bioprocessing labs include:

• Chromatography momentum: Growing over 25% year-over-year, chromatography continues to be a high-priority investment area for labs scaling up production.
• Consumable stability: Consumable revenue grew by double digits, signaling that existing bioprocessing installations are maintaining high utilization rates.
• Biotech rebound: Emerging biotech customers grew by more than 20%, suggesting a revitalization in the early-to-mid-stage drug development pipeline.

Strategic divestiture and the "Transformation Office."

Repligen is also undergoing a significant internal realignment. On March 30, 2026, the company completed the divestiture of its Polymem operations. This move allows Repligen to shed non-core assets and focus more heavily on its core bioprocessing technologies.

Furthermore, the company announced the launch of a Transformation Office. For the laboratory community, this typically points to:

• Operational efficiency: Streamlining the global manufacturing footprint to ensure more reliable lead times and product availability.
• Margin expansion: Reinvesting savings into R&D for next-generation filtration and protein technologies.
• Strategic partnerships: Repligen recently signed a partnership for manufacturing in China, which led to a near doubling of revenue in that region during Q1.

Regional trends: A surge in China

While North American growth remained modest at 5%, the APAC region saw a massive 29% jump. This was driven primarily by a "near doubling" of revenue in China. Lab managers with global operations should note that supply chain and manufacturing capacity in the APAC region are becoming increasingly central to Repligen’s strategy.

Procurement and operations briefing: Insights for lab managers

For lab managers and procurement heads, Repligen’s Q1 results offer more than just financial metrics; they provide a roadmap for where the bioprocessing industry is heading in 2026.

1. Accelerated move to "Bioprocessing 4.0" - The 50% growth in Process Analytics—far outpacing other segments—indicates that your peers are aggressively moving away from manual, offline sampling. Managers should evaluate current workflows for opportunities to integrate real-time monitoring (e.g., FlowVPE or CTech platforms). These tools reduce sampling risk and batch-to-batch variability, which is critical for labs working under strict GMP guidelines or tight production schedules.

Advanced Lab Management Certificate

The Advanced Lab Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

2. Supply chain predictability and the "Transformation Office - The launch of the Transformation Office is a direct response to the supply chain volatility of previous years. For lab managers, this office represents a push toward a more "resilient and simplified" manufacturing footprint. This likely means:

• Improved lead times: By divesting Polymem and focusing on core assets, Repligen is concentrating on the high-demand filtration and chromatography products that labs rely on most.
• Inventory reliability: The consolidation of manufacturing often leads to a "safety stock" strategy that is easier for vendors to manage, reducing the risk of unexpected backorders for critical consumables.

3. Navigating the Polymem divestiture - Labs utilizing Polymem-specific filtration solutions should immediately review their inventory and long-term supply agreements. While Repligen is focusing on its core franchises, this divestiture signals that niche filtration products may undergo a transition in support or branding. Lab managers should confirm with their Repligen representative if any specific part numbers in their SOPs are affected.

4. Regional sourcing advantages - With Repligen nearly doubling its revenue in China and signing new manufacturing partnerships in the region, labs with APAC-based facilities may see improved local support and faster fulfillment. Conversely, North American managers should monitor if this global shift results in a change to local distribution hubs or account management structures.

5. Budgeting for scalability - With emerging biotech growing at 20%+, Repligen is prioritizing scalable solutions. For labs in the growth phase, now is the time to negotiate "scale-up" contracts that cover the transition from benchtop to pilot scale, ensuring that the same chromatography and filtration technologies can follow the molecule throughout its lifecycle without significant re-validation.

Repligen remains a pivotal partner for labs moving toward high-efficiency standards. As the company optimizes its footprint and doubles down on automated analytics, lab managers have a unique opportunity to align their procurement strategies with these high-growth, high-efficiency trends.